<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39117891</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2509-8020</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of patient-reported outcomes</Title><ISOAbbreviation>J Patient Rep Outcomes</ISOAbbreviation></Journal><ArticleTitle>The symptoms evolution of long COVID&#x2011;19 (SE-LC19): a new patient-reported content valid instrument.</ArticleTitle><Pagination><StartPage>87</StartPage><MedlinePgn>87</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">87</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41687-024-00737-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The field of long COVID research is rapidly evolving, however, tools to assess and monitor symptoms and recovery of the disease are limited. The objective of the present study was to develop a new patient-reported outcomes instrument, the Symptoms Evolution of Long COVID&#x2011;19 (SE-LC19), and establish its content validity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The 40-item SE-LC19 instrument was developed based on patient-relevant empirical evidence from scientific literature and clinical guidelines that reported symptoms specific to long COVID. A 2-part mixed-method approach was employed. Part 1: Qualitative interviews with a purposive sample of 41 patients with confirmed long COVID were conducted for the content validation of SE-LC19. During cognitive debriefing interviews, patients were asked to describe their understanding of the instrument's instructions, specific symptoms, response options, and recall period to ensure its relevance and comprehensiveness. Five clinicians of different medical specialties who regularly treated patients with long COVID were also interviewed to obtain their clinical expert opinions on SE-LC19. Part 2: Exploratory Rasch Measurement Theory (RMT) analysis was conducted to evaluate the psychometric properties of the SE-LC19 data collected during the interviews.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, patients reported that the instructions, questions, recall period, and response options for SE-LC19 were comprehensive and relevant. Minor conceptual gaps reported by patients captured nuances in the experience of some symptoms that could be considered in future studies. Some patients suggested a revision of the recall period from 24&#xa0;h to 7&#xa0;days to be able to capture more symptoms given the waxing and waning nature of some symptoms. Clinicians found the instrument comprehensive with minimal suggestions regarding its content. Exploratory RMT analyses provided evidence that the SE-LC19 questionnaire performed as intended.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The present mixed-methods study in patients with confirmed long COVID supports the content validity and applicability of the SE-LC19 instrument to evaluate the symptoms of patients with long COVID. Further research is warranted to explore the psychometric properties of the instrument and refine a meaningful and robust patient-relevant endpoint for use in different settings such as clinical trials and clinical practice to track the onset, severity, and recovery of long COVID.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rofail</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA. diana.rofail@regeneron.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Somersan-Karakaya</LastName><ForeName>Selin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mylonakis</LastName><ForeName>Eleftherios</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Infectious Diseases Division, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Julia Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Modus Outcomes, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przydzial</LastName><ForeName>Krystian</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Modus Outcomes, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquis</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Modus Outcomes, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Norton</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Podolanczuk</LastName><ForeName>Anna J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geba</LastName><ForeName>Gregory P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Regeneron Pharmaceuticals, Inc., 1 Rockwood Road, Sleepy Hollow, NY, 10591, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Regeneron Pharmaceuticals</Agency><Country/></Grant><Grant><GrantID>HHSO100201700020C</GrantID><Agency>Department of Health and Human Services, Office of the Administration for Strategic Preparedness and Response, and Biomedical Advanced Research and Development Authority</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Patient Rep Outcomes</MedlineTA><NlmUniqueID>101722688</NlmUniqueID><ISSNLinking>2509-8020</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="Y">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="Y">Psychometrics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Long haulers</Keyword><Keyword MajorTopicYN="N">Long-haul COVID</Keyword><Keyword MajorTopicYN="N">Patient-reported outcome measures</Keyword><Keyword MajorTopicYN="N">Patient-reported outcomes</Keyword><Keyword MajorTopicYN="N">Post-COVID conditions</Keyword><Keyword MajorTopicYN="N">Qualitative</Keyword><Keyword MajorTopicYN="N">Questionnaire</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList><CoiStatement>D.R. is a Regeneron Pharmaceuticals, Inc. employee/stockholder, and former Roche employee and current stockholder. S.S.-K., Y.Z., M.H., T.D.N., and G.P.G. are employees/stockholders at Regeneron Pharmaceuticals, Inc. EM reports payments to his institution received from SciClone Pharmaceuticals, Regeneron Pharmaceuticals, Inc., Pfizer, Chemic Labs/KODA Therapeutics, Cidara, and Leidos Biomedical Research Inc./NCI; and reports advisory board: Basilea; and grants from NIH/NIAID, NIH/NIGMS, and BARDA. J.Y.C., and K.P. are employees of Modus Outcomes and consulted for Regeneron Pharmaceuticals, Inc. A.J.P. reported receiving personal fees from Regeneron Pharmaceuticals, Inc. during the conduct of the study, personal fees from Imvaria, Boehringer Ingelheim, EBSCO/Dynamed, and Roche outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>8</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39117891</ArticleId><ArticleId IdType="pmc">PMC11310370</ArticleId><ArticleId IdType="doi">10.1186/s41687-024-00737-5</ArticleId><ArticleId IdType="pii">10.1186/s41687-024-00737-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vanichkachorn G, Newcomb R, Cowl CT et al (2021) Post-COVID-19 syndrome (long haul syndrome): description of a multidisciplinary clinic at Mayo Clinic and characteristics of the initial patient cohort. Mayo Clin Proc 96:1782&#x2013;1791 10.1016/j.mayocp.2021.04.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2021.04.024</ArticleId><ArticleId IdType="pmc">PMC8112396</ArticleId><ArticleId IdType="pubmed">34218857</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P (2021) Long covid-mechanisms, risk factors, and management. BMJ 374:n1648 10.1136/bmj.n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html</Citation></Reference><Reference><Citation>Callard F, Perego E (2021) How and why patients made Long Covid. Soc Sci Med 268:113426 10.1016/j.socscimed.2020.113426</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Preston N, Parkin A et al (2022) The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome. J Med Virol 94:4253&#x2013;4264 10.1002/jmv.27878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27878</ArticleId><ArticleId IdType="pmc">PMC9348420</ArticleId><ArticleId IdType="pubmed">35603810</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DA, O&#x2019;Brien KK (2021) Conceptualising Long COVID as an episodic health condition. BMJ Glob Health 6:e007004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8460526</ArticleId><ArticleId IdType="pubmed">34551971</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L et al (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38:101019 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Nearly one in five American adults who have had COVID-19 still have &#x201c;long COVID&#x201d;. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm</Citation></Reference><Reference><Citation>Rofail D, Somersan-Karakaya S, Choi JY et al (2024) Thematic analysis to explore patients&#x2019; experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives. BMJ Open 14:e076992 10.1136/bmjopen-2023-076992</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-076992</ArticleId><ArticleId IdType="pmc">PMC10806796</ArticleId><ArticleId IdType="pubmed">38233059</ArticleId></ArticleIdList></Reference><Reference><Citation>Rofail D, McGale N, Im J et al (2022) Development and content validation of the symptoms evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies. J Patient Rep Outcomes 6:41 10.1186/s41687-022-00448-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-022-00448-9</ArticleId><ArticleId IdType="pmc">PMC9066128</ArticleId><ArticleId IdType="pubmed">35507193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rofail D, McGale N, Podolanczuk AJ et al (2022) Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients. BMJ Open 12:e055989 10.1136/bmjopen-2021-055989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-055989</ArticleId><ArticleId IdType="pmc">PMC9062460</ArticleId><ArticleId IdType="pubmed">35501077</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Coronavirus disease (COVID-19): post COVID-19 condition. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition</Citation></Reference><Reference><Citation>U.S. Department of Health Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health Human Services FDA Center for Devices and Radiological Health (2006) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes 4:79</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1629006</ArticleId><ArticleId IdType="pubmed">17034633</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient&#x2019;s voice in medical product development and regulatory decision making. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-collecting-comprehensive-and-representative-input</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-methods-identify-what-important-patients</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome</Citation><ArticleIdList><ArticleId IdType="pubmed">37116698</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory</Citation></Reference><Reference><Citation>Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19:349&#x2013;357 10.1093/intqhc/mzm042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intqhc/mzm042</ArticleId><ArticleId IdType="pubmed">17872937</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidy NK, Vernon M (2008) Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics 26:363&#x2013;370 10.2165/00019053-200826050-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200826050-00002</ArticleId><ArticleId IdType="pubmed">18429654</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyrick J (2006) What is good qualitative research? A first step towards a comprehensive approach to judging rigour/quality. J Health Psychol 11:799&#x2013;808 10.1177/1359105306066643</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1359105306066643</ArticleId><ArticleId IdType="pubmed">16908474</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. https://www.fda.gov/media/77832/download</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1629006</ArticleId><ArticleId IdType="pubmed">17034633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SE, Haroon S, Subramanian A et al (2022) Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. BMJ 377:e070230 10.1136/bmj-2022-070230</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070230</ArticleId><ArticleId IdType="pmc">PMC9043395</ArticleId><ArticleId IdType="pubmed">35477524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R (2021) Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument. Health Qual Life Outcomes 19:229 10.1186/s12955-021-01862-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-021-01862-1</ArticleId><ArticleId IdType="pmc">PMC8477362</ArticleId><ArticleId IdType="pubmed">34583690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan M, Halpin S, Gee J (2020) Assessing long-term rehabilitation needs in COVID-19 survivors using a telephone screening tool (C19-YRS tool). Adv Clin Neurosci Rehabil 19:14&#x2013;1710.47795/NELE5960</Citation><ArticleIdList><ArticleId IdType="doi">10.47795/NELE5960</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V-T, Riveros C, Clepier B et al (2022) Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: a Set of Patient-Reported Instruments Constructed From Patients&#x2019; Lived Experience. Clin Infect Dis 74:278&#x2013;287 10.1093/cid/ciab352</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab352</ArticleId><ArticleId IdType="pmc">PMC8135558</ArticleId><ArticleId IdType="pubmed">33912905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood DC et al (2020) Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med 52:jrm00063</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics (2021) Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. Available at https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021</Citation></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M et al (2022) Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun 13:1957 10.1038/s41467-022-29521-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff AL, Lipkin WI (2023) ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med (Lausanne) 10:1187163 10.3389/fmed.2023.1187163</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1187163</ArticleId><ArticleId IdType="pmc">PMC10278546</ArticleId><ArticleId IdType="pubmed">37342500</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>